MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
0.5500
+0.0555
+11.22%
Closed 16:00 03/18 EDT
OPEN
0.5500
PREV CLOSE
0.4945
HIGH
0.5705
LOW
0.5500
VOLUME
106.37K
TURNOVER
0
52 WEEK HIGH
1.650
52 WEEK LOW
0.3377
MARKET CAP
18.38M
P/E (TTM)
-0.6102
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Applied DNA Sciences (APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. XTL Biopharmaceuticals (XTLB) shares increased by 19.31%. 2seventy bio (TSVT) shares rose 17.7%. Titan Pharma (TTNP) shares declined by 18.2% during the session.
Benzinga · 17h ago
Weekly Report: what happened at MBRX last week (0311-0315)?
Weekly Report · 20h ago
Weekly Report: what happened at MBRX last week (0304-0308)?
Weekly Report · 03/11 10:33
12 Health Care Stocks Moving In Monday's After-Market Session
Vicarious Surgical shares moved upwards by 24.9% to $0.45 during Monday's after-market session. The company's, Q4 earnings came out today. Ekso Bionics Holdings (NASDAQ:EKSO) stock increased by 21.42% in the same session.
Benzinga · 03/04 21:32
Weekly Report: what happened at MBRX last week (0226-0301)?
Weekly Report · 03/04 10:36
Moleculin Biotech Hosts Virtual Investor Strategy Call
TipRanks · 02/29 13:43
Weekly Report: what happened at MBRX last week (0219-0223)?
Weekly Report · 02/26 10:45
Moleculin Biotech’s Leadership Shares Company Insights
TipRanks · 02/22 14:45
More
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. Annamycin is in development for the treatment of refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.